51
Participants
Start Date
March 31, 2007
Primary Completion Date
August 31, 2010
Study Completion Date
August 31, 2012
MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)
MYDICAR administered by antegrade epicardial coronary artery infusion
Placebo Infusion
Saline; epicardial coronary artery infusion
MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
MYDICAR administered by antegrade epicardial coronary artery infusion
Mount Sinai Medical Center, New York
Columbia University Hospital, New York
University of Pittsburgh Medical Center, Presbyterian-Shadyside Hospital, Pittsburgh
Hospital of the University of Pennsylvania, Philadelphia
Wake Forest University, Winston-Salem
Shands Hospital at University of Florida, Gainesville
Tennessee Center for Clinical Trials & Harton Regional Medical Center, Tullahoma
MetroHealth Medical Center, Cleveland
Cleveland Clinic Foundation, Cleveland
University of Cincinnati, Cincinnati
University of Wisconsin, Madison
Northwestern University, Chicago
University of Chicago Medical Center, Chicago
St. Louis University Hospital, St Louis
Mid America Heart Institute, Saint Luke's Hospital, Kansas City
Cardiopulmonary Research Science and Technology Institute, Medical City Dallas Hospital, Dallas
Methodist Hospital, Houston
Intermountain Medical Center, Murray
University of California at San Diego Medical Center, San Diego
San Diego Cardiac Center, San Diego
Oregon Health and Science University, Portland
University of Medicine and Dentistry of New Jersey, Newark
Lead Sponsor
Celladon Corporation
INDUSTRY